194 results about "Influenza prevention" patented technology

Recombinant influenza virus proteins, including influenza capsomers, subviral particles, virus-like particles (VLP), VLP complexes, and / or any portions of thereof, are provided as a vaccine for influenza viruses. The invention is based on the combination of two vaccine technologies: (1) intrinsically safe recombinant vaccine technology, and (2) highly immunogenic, self-assembled protein macromolecules embedded in plasma membranes and comprised of multiple copies of influenza virus structural proteins exhibiting neutralizing epitopes in native conformations. More specifically, this invention relates to the design and production of functional homotypic and heterotypic recombinant influenza virus-like particles (VLPs) comprised of recombinant structural proteins of human influenza virus type A / Sydney / 5 / 94 (H3N2) and / or avian influenza virus type A / Hong Kong / 1073 / 99 (H9N2) in baculovirus-infected insect cells and their application as a vaccine in the prevention of influenza infections and as a laboratory reagent for virus structural studies and clinical diagnostics.

Compounds of formula (I) or their salts or esters:have excellent sialidase inhibitory activity and are therefore useful for the treatment and prevention of influenza and other viral diseases where the replication of the virus is susceptible to sialidase inhibitors.

This invention is directed to methods for treating and preventing influenza infection by inhibiting influenza virus HA maturation processes employing compounds of formula I. It is also directed to combinations for treating and preventing influenza infection comprising compounds of formula I and other agents.

The present invention relates inter alia to the treatment or prevention of influenza virus infection (including subtypes influenza A virus, influenza B virus, avian strain H5N1, A / H1N1, H3N2 and / or pandemic influenza) using compounds which inhibit the activity of p59-HCK and to a method of screening for a candidate drug substance intended to prevent or treat influenza virus infection in a subject, said method comprising identifying a test substance capable of inhibiting p59-HCK activity.

This invention is directed to methods for treating and preventing influenza infection by inhibiting influenza virus HA maturation processes employing compounds of formula I. It is also directed to combinations for treating and preventing influenza infection comprising compounds of formula I and other agents.

The invention relates to pharmaceutical compositions that contain a calcium salt as an active ingredient and also comprise another anti-influenza agent, and to methods for treating or preventing influenza virus infection.

Attenuated influenza virus variants comprising substitutions in NS1 that interfere with viral replication and phosphatidylinositol 3-kinase activation are described. NS1 variant polypeptides, polynucleotides encoding NS1 variant polypeptides, a reverse genetics system for producing attenuated influenza virus NS1 variants, immunogenic compositions comprising live attenuated influenza virus NS1 variants, methods of stimulating an immune response against influenza virus, methods of interfering with influenza virus replication, and methods of treating and preventing influenza virus infection are described.

The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and vaccines useful in prevention of infection by influenza virus. Provided are recombinant protein antigens, compositions, and methods for the production and use of such antigens and vaccine compositions.

The invention provides human scFv antibodies and monoclonal antibodies that neutralize influenza virus. Also provided are methods of treating and / or preventing a influenza related disease or disorder such bird flu The invention also provides methods of vaccinating a patient against influenza. Also provided are methods of diagnosing influenza-related diseases or disorders and methods of detecting the presence of a influenza in a sample.

The present invention provides methods for treating or preventing influenza virus infection. The methods of the present invention comprise administering to a subject in need thereof a pharmaceutical composition comprising a type II transmembrane serine protease (TTSP) inhibitor. The TTSP inhibitor preferably functions by inhibiting the proteolytic cleavage of influenza hemagglutinin (HA0) into the functional subunits HA1 and HA2. In certain embodiments, the TTSP inhibitor is an inhibitor of transmembrane protease serine S1 member 2 (TMPRSS2), such as an anti-TMPRSS2 antibody or antigen-binding fragment thereof.

The invention relates to a rice aroma beef sauce and a preparation method thereof. The rice aroma beef sauce is characterized in that the rice aroma beef sauce is prepared from the following raw materials by weight: 50-55 parts of beef, 2-2.4 parts of creeping liriope, 1-1.2 parts of equisetum hyemale l, 0.8-1 part of american ginseng, 1-1.2 parts of rehmannia glutinosa(gae-rtn.) libosch, 0.9-1 part of gerbera anandria (linn.)sch.-bip, 1.1-1.4 parts of monochoria vaginalis, 3-4 parts of propolis, 7-8 parts of hulless barley powder, 3-4 parts of capsella bursa-pastoris, 4-5 parts of flammulina velutipes, 4-4.5 parts of garlic sprouts, 22-25 parts of sunflower seed kernel, 30-35 parts of glutinous rice, 10-11 parts of crab meat, 0.1-0.2 part of a composite flavor protease, 350-370 parts of sweet flour paste, and 4-5 parts of a nutritional additive. According to the present invention, the aroma and the sweet taste of the glutinous rice and the delicious taste of the crab meat are fused into the rice aroma beef sauce, such that the rice aroma beef sauce has the unique flavor; the rice aroma beef sauce is rich in nutrition, wherein the hulless barley powder is rich in dietary fibers so as to remove toxins from the body, and the garlic sprouts contain capsaicine so as to provide effects of sterilization and influenza prevention; and the rice aroma beef sauce further contains a variety of Chinese herbal ingredients so as to provide effects of lung moisturizing, heart-fire clearing, eyesight improving, nebula removing, qi reinforcing and yin nourishing after regular taking.

The invention relates to a robot with environment monitoring and haze removal, formaldehyde removal and sterilization functions. The robot comprises a robot head (1), a connecting part (2), a torso (3), an air monitoring device (4) and a haze removal and formaldehyde removal sterilization device (5), wherein the robot head (1) is rotationally connected with the connecting part (2), and the robot head (1) and the connecting part (2) are fixedly connected to the torso (3); and the air monitoring device (4) is wirelessly connected with the robot head (1), and the haze removal and formaldehyde removal sterilization device (5) is wirelessly connected with the robot head (1). The robot with the environment monitoring and haze removal, formaldehyde removal and sterilization functions can monitorthe air quality, meanwhile, the robot can intelligently turn on the air purification function or the ozone sterilization and disinfection function according to the air quality condition, the occupiedspace is small, and the use is convenient, in addition, the robot can analyze the body temperature health condition of people in the flu season through face recognition and body temperature detection,the robot can provide early warning for people with significantly elevated body temperature, and the effect of influenza prevention is achieved.

The present invention relates inter alia to the treatment or prevention of influenza virus infection (including subtypes influenza A virus, influenza B virus, avian strain H5N1, A / H1N1, H3N2 and / or pandemic influenza) using compounds which inhibit the activity of p59-HCK and to a method of screening for a candidate drug substance intended to prevent or treat influenza virus infection in a subject, said method comprising identifying a test substance capable of inhibiting p59-HCK activity.

The invention provides a traditional Chinese medicine scented sachet for preventing influenza. The scented sachet is characterized in that medicines in the scented sachet give off persistent aromatic odor, which stimulates the respiratory mucosa of the human body to generate secreted immunoglobulin A, and such an antibody has a strong action of killing virus and bacteria, so that these microorganisms can not survive on the upper respiratory mucosa, thus achieving the effect of preventing infectious diseases. The traditional Chinese medicine scented sachet can effectively prevent influenza.

The invention provides an azacyclo diketone compound, which is a compound represented by the following structure defined in the specification, or a pharmaceutically acceptable salt thereof. The invention provides a compound having an inhibitory activity on influenza (flu) virus proliferation, particularly on influenza-related cap-dependent endonuclease to inhibit influenza virus proliferation so as to treat or prevent influenza. The present invention relates to a substituted azacyclo diketone compound having inhibitory activity on cap-dependent endonuclease, and a pharmaceutical composition containing the substituted azacyclo diketone compound.

A multi-component immunogenic composition confers protection on an immunized host against infection caused by Haemophilus influenzae. Such composition comprises at least three different antigens of Haemophilus influenzae, two of which are adhesins. High molecular weight (HMW) proteins and Haemophilus influenzae adhesin (Hia) proteins of non-typeable Haemophilus influenzae comprise the adhesin components while the other antigen is a non-proteolytic analog of Hin47 protein. Each component does not impair the immunogenicity of the others. The Haemophilus vaccine may be combined with DTP component vaccines, which may contain inactivated poliovirus, including type 1, type 2 and / or type 3, and / or a conjugate of a capsular polysaccharide of Haemophilus influenzae and tetanus or diphtheria toxoid, including PRP-T, to provide a multi-valent component vaccine without impairment of the immunogenic properties of the other antigens.

The present invention relates to mRNA sequences usable as mRNA-based vaccines against infections with influenza viruses. Additionally, the present invention relates to a composition comprising the mRNA sequences and the use of the mRNA sequences or the composition for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of influenza virus infections. The present invention further describes a method of treatment or prophylaxis of infections with influenza virus using the mRNA sequences.

This invention relates to new safe botanical drug, which is used for treatment and prevention of influenza and increasing immune function. Specifically, this invention provides a method for producing pure Banlangensu (PBLG), BLG's Polysaccharide and Isatin B.

The present invention provides methods for treating or preventing influenza virus infection. The methods of the present invention comprise administering to a subject in need thereof a pharmaceutical composition comprising a type II transmembrane serine protease (TTSP) inhibitor. The TTSP inhibitor preferably functions by inhibiting the proteolytic cleavage of influenza hemagglutinin (HA0) into the functional subunits HA1 and HA2. In certain embodiments, the TTSP inhibitor is an inhibitor of transmembrane protease serine S1 member 2 (TMPRSS2), such as an anti-TMPRSS2 antibody or antigen-binding fragment thereof.

The invention relates to an anti-influenza and anti-avian influenza medicament, wherein the chemical name is (1S, 2S, 3R, 4R)-3-((1S)-1-acetamido-2-ethyl-butyl)-4-guanidino-2-hydroxy-cyclopentyl-1-carboxylic acid, the structure is as shown in the figure (the compound is called compound A for short), and different groups are connected on carboxyl or / and amino of the compound A in the research to get the derivatives of the compound A. The derivatives can be combined with pharmaceutically acceptable excipients to be used for treating and / or preventing influenza and avian influenza.

The invention discloses an application of berberine in medicine for treating or preventing influenza virus. The application proves that berberine enjoys the good function of resisting influenza virus on MDCK cells infected by A-type influenza virus such as H5N1 and H3N2 and on A549 cells.Meanwhile, the berberine can kill influenza virus to a certain extent, prevent attack from the influenza virusand inhibit cells infected by the influenza virus; the berberine enjoys similar effect to amantadine, a positive control medicine; in addition, the berberine can well inhibit inflammatory responses triggered by the influenza virus and is disclosed to enjoy the prospect of being developed into the medicine for resisting the influenza virus.

The present invention provides a composition for treating and / or preventing influenza, a method and an application thereof. The composition contains protein treated with acid anhydride and another drug for treating and / or preventing influenza. The acid anhydride-treated protein prepared by the invention is acid anhydride-treated lactoglobulin. An in vitro experiment shows that the protein can broadly inhibit influenza virus infected cells of various subtypes. In animal in vivo experiments, the protein has a significant prevention and treatment effect on influenza virus infection. Influenza viruses have many subtypes and high mutation rates, so that the development of broad-spectrum anti-influenza preparations is very important. The acid anhydride-treated protein can not only inhibits the infection of many seasonal influenza viruses, but also significantly inhibits the highly pathogenic avian influenza virus H7N9, and the influenza virus H1N1 (2009) which caused a pandemic, suggesting that the protein can be developed as a highly effective and broad-spectrum biological preparation for the prevention and treatment of influenza viruses.

The invention relates to a respiratory system protecting appliance, in particular to a mask capable of preventing and curing haze and influenza. The mask comprises a mask body and ear hangers, wherein the mask body covers the face, the mouth and the nose of a user; the ear hangers are connected to two short edges of the mask body and are hung on ears of the user; the mask body comprises two layers of cloth, two layers of filtering plates and a plastic nose strip; the two layers of filtering plates are arranged between the two layers of cloth; the plastic nose strip is concealed in the outer layer of cloth; the first layer of cloth is in contact with an external environment direction; the second layer of cloth is adhered to the face, the mouth and the nose of the user and is in contact with the user direction; and the filter plates comprise a filter plate which has a four-layered structure and a filter plate which has a three-layered structure and is filled with Chinese herb extracts. The mask can effectively resist PM (particulate matter) 2.5, and can also prevent influenza; a mask body can be cleaned; the filtering plates of the mask can be changed; the filtering efficiency, the breathability and the antibacterial property of the filtering plates of the mask can be obviously improved; the mask is simple in structure and comfortable to wear; and health of human bodies is facilitated.

The invention relates to a preparation method and application of a total extractive of artemisia rupestris L. The method comprises the following steps of: crushing a dry artemisia rupestris L. medicinal material, extracting by using ethanol as an organic solvent, carrying out resin separation and purification to obtain the total extractive of the artemisia rupestris L., wherein the total extractive of the artemisia rupestris L. mainly contains sesquiterpenoids and flavonoid constitutes, a sesquiterpenoid and the flavonoid constitute compound is in the mass percentage of 25-90%, a sesquiterpenoid compound is in the mass percentage of 5-25%, a flavonoid constitute compound is in the mass percentage of 20-65%, and rupestonic acid of the sesquiterpenoid compound is in the mass percentage of 3-15%. Proved by a primary activity screening test, the total extractive of the artemisia rupestris L., obtained by using the method provided by the invention, has remarkable in vitro and vivo influenza virus resistance, bacteriostasis and sterilization effects and can also be used for effectively preventing influenza viruses. The method disclosed by the invention is simple in process, free of high-temperature and high-pressure equipment, low in production cost, stable in quality of effective components and easy to control.

The invention relates to a preparation for preventing influenza, which contains the following components in percentage: 10 percent of heterophylly falsestarwort root, 20 percent of bupleurum root, 6 percent of tuckahoe, 20 percent of licorice root and 44 percent of honeysuckle. The form of the preparation for preventing the influenza is capsules, sugar granules, sugar-free granules, tablets or oral liquid. (1) The bupleurum root contained in the preparation has anti-febrile, analgesia and anti-inflammatory effects and has little injury to the liver. (2) The tuckahoe contained in the preparation has sweet character and taste, has the effects of excreting dampness and tonifying spleen, quickens metabolism, and has low side effect.

The invention discloses a primer composition for detecting different influenza viruses and an application thereof. The primer composition disclosed by the invention comprises any one of primer pairs represented by the following (1)-(4): (1) a DNA molecule shown in SEQ ID No.1 and a DNA molecule shown in SEQ ID No.2; (2) a DNA molecule shown in SEQ ID No.3 and a DNA molecule shown in SEQ ID No.4; (3) a DNA molecule shown in SEQ ID No.5 and a DNA molecule shown in SEQ ID No.6; and (4) a DNA molecule shown in SEQ ID No.7 and a DNA molecule shown in SEQ ID No.8. The primer composition has positive meanings on timely diagnosing and timely treating pathogenetic canine, timely forecasting epidemic trends, preventing influenza large pandemic, and implementing large-scale canine influenza virus epidemiology monitoring.

Recombinant, chimeric porcine influenza viruses are disclosed that include hemagglutinin segments from more than one influenza virus subtype. Also described are methods of producing the recombinant influenza viruses, immunogenic compositions comprising the recombinant influenza viruses, methods of stimulating an immune response against influenza virus, and methods of treating and preventing influenza virus infection.